Biotech Investor Relations Activity Record Form (2024 Semi-Annual Science and Technology Innovation Board Pharmaceutical and Biological Products Group Performance Briefing)
Biotech Investor Activity Record Form (2024 Investor Online Group Reception Day Event in Guangdong Province)
Baiaotai\'s announcement on participating in the 2024 Semi-Annual Science and Technology Innovation Board Special Group Performance Briefing on Pharmaceuticals and Biological Products
Baiaotai\'s announcement on participating in the 2024 Investor Online Group Reception Day in Guangdong
Biotech voluntarily disclosed the notice of approval for dupriumab injection (BAT2406) for drug clinical trials
Biotech voluntarily disclosed the notice of approval for clinical trials of BAT8006 combined with bevacizumab
China International Finance Co., Ltd.'s verification opinion on Bio-Thera Solutions Co., Ltd.'s use of part of the idle funds raised to temporarily supplement working capital.
Bio-Thera Solutions' Announcement Regarding the Temporary Supplement of Working Capital Using Some Idle Raised Funds
Bio-Thera Solutions' semi-annual evaluation report on the special action plan for improving quality and efficiency and returning to profitability in the company for the year 2024.
Announcement of the resolution of the 15th meeting of the second board of supervisors of Bio-Thera Solutions.
Bio-Thera Solutions Special Report on the Deposit and Actual Use of Funds Raised in the First Half of 2024
Bio-Thera Solutions Announcement on the Return of Idle Fund Raised for Temporary Working Capital Supplement.
Bio-Thera Solutions voluntarily disclosed the announcement about the acceptance of the application for the marketing authorization of BAT2206 (Ustekinumab Injection) by the US FDA and the European Medicines Agency (EMA).
Bio-Thera Solutions Investor Event Record (July 18, 2024)
Bio-Thera Solutions Investor Event Record (July 4, 2024)
Bio-Thera Solutions Announcement on the pharmaceutical registration certificate of citrate-conjugated belimumab injection (Betanin).
Bio-Thera Solutions' Announcement Regarding Government Grants.
Biotech voluntarily disclosed the announcement that BAT8008 combined with bevacizumab or combined BAT7104 obtained a notice of approval for drug clinical trials
Biotech voluntarily disclosed the announcement that BAT6005 and BAT1308 injections obtained approval letters for drug clinical trials
Biotech voluntarily disclosed the announcement that BAT1308 and BAT8006 obtained a notice of approval for drug clinical trials
No Data
No Data